MonoFIX-VF New Zealand - English - Medsafe (Medicines Safety Authority)

monofix-vf

csl behring (nz) ltd - factor ix 500 [iu] (human coagulation 100iu/ml when reconstituted with 5ml water for injections) - injection with diluent - 500 iu - active: factor ix 500 [iu] (human coagulation 100iu/ml when reconstituted with 5ml water for injections) excipient: antithrombin iii chloride citric acid monohydrate heparin phosphorus plasma protein fraction sodium water for injection - monofix®-vf is indicated for the treatment of haemorrhages, for use in surgery, and as prophylaxis in patients with haemophilia b. monofix®-vf is not indicated for the treatment of factor ii, vii or x deficiencies because it does not contain therapeutic levels of these coagulation factors. monofix®-vf is not indicated for the treatment of haemophilia a patients with factor viii inhibitors.

MonoFix-VF New Zealand - English - Medsafe (Medicines Safety Authority)

monofix-vf

csl behring (nz) ltd - factor ix 500 [iu] (50 iu/ml when reconstituted with 10 ml water for injections) - injection with diluent - 50 iu/ml - active: factor ix 500 [iu] (50 iu/ml when reconstituted with 10 ml water for injections) excipient: antithrombin iii chloride citric acid monohydrate heparin phosphorus plasma protein fraction sodium water for injection - monofix®-vf is indicated for the treatment of haemorrhages, for use in surgery, and as prophylaxis in patients with haemophilia b. monofix®-vf is not indicated for the treatment of factor ii, vii or x deficiencies because it does not contain therapeutic levels of these coagulation factors. monofix®-vf is not indicated for the treatment of haemophilia a patients with factor viii inhibitors.

HEMOFIL M ANTIHEMOPHILLIC FACTOR (HUMAN) METHOD M MONOCLONAL PURIFIED Israel - English - Ministry of Health

hemofil m antihemophillic factor (human) method m monoclonal purified

takeda israel ltd - factor viii (human) - powder for solution for injection - factor viii (human) 220 - 2000 iu/vial - coagulation factor viii - coagulation factor viii - hemophilia a - for the prevention and control of hemorrhagic episodes

FEIBA NF KIT Canada - English - Health Canada

feiba nf kit

takeda canada inc - anti-inhibitor coagulant complex - kit - 1300unit - anti-inhibitor coagulant complex 1300unit - hemostatics

FEIBA NF KIT Canada - English - Health Canada

feiba nf kit

takeda canada inc - anti-inhibitor coagulant complex - kit - 3250unit - anti-inhibitor coagulant complex 3250unit - hemostatics

BIOSTATE human coagulation factor VIII 1000IU/ von Willebrand factor 2400IU powder for injection vial with diluent vial Australia - English - Department of Health (Therapeutic Goods Administration)

biostate human coagulation factor viii 1000iu/ von willebrand factor 2400iu powder for injection vial with diluent vial

csl behring australia pty ltd - factor viii, quantity: 1000 iu; von willebrand factor, quantity: 2400 iu - injection, diluent for - excipient ingredients: - the prophylaxis and treatment of non-surgical and surgical bleeding in patients with von willebrand disease when desmopressin (ddavp) treatment is ineffective or contraindicated. the prophylaxis and treatment of non-surgical and surgical bleeding associated with factor viii deficiency due to haemophilia a.

MONOFIX-VF human coagulation factor IX 1000IU powder for injection vial and 10 mL diluent vial Australia - English - Department of Health (Therapeutic Goods Administration)

monofix-vf human coagulation factor ix 1000iu powder for injection vial and 10 ml diluent vial

csl behring australia pty ltd - factor ix, quantity: 1000 iu - injection, powder for - excipient ingredients: phosphate; plasma proteins; antithrombin iii; heparin sodium; sodium; citrate; chloride - monofix-vf is indicated for the treatment of haemorrhages, for use in surgery, and as prophylaxis in patients with haemophilia b. monofix-vf is not indicated for the treatment factor ii, vii or x deficiencies because it does not contain therapeutic levels of these coagulation factors. monofix-vf is not indicated for the treatment of haemophilia a patients with factor viii inhibitors.

MONOFIX-VF human coagulation factor IX 500IU powder for injection vial and 5mL diluent vial Australia - English - Department of Health (Therapeutic Goods Administration)

monofix-vf human coagulation factor ix 500iu powder for injection vial and 5ml diluent vial

csl behring australia pty ltd - factor ix, quantity: 500 iu - injection, powder for - excipient ingredients: citrate; heparin sodium; antithrombin iii; sodium; chloride; plasma proteins; phosphate - monofix-vf is indicated for the treatment of haemorrhages, for use in surgery, and as prophylaxis in patients with haemophilia b. monofix-vf is not indicated for the treatment factor ii, vii or x deficiencies because it does not contain therapeutic levels of these coagulation factors. monofix-vf is not indicated for the treatment of haemophilia a patients with factor viii inhibitors.

FEIBA NF KIT Canada - English - Health Canada

feiba nf kit

takeda canada inc - anti-inhibitor coagulant complex - kit - 650unit - anti-inhibitor coagulant complex 650unit - hemostatics

FEIBA NF KIT Canada - English - Health Canada

feiba nf kit

takeda canada inc - anti-inhibitor coagulant complex - kit - 650unit - anti-inhibitor coagulant complex 650unit - hemostatics